The Expression Of SOCS3in Cell Models And Difficult To Treat Chronic Hepatitis B Patients’ PBMC

Objective: Recent studies revealed that SOCS3(suppressor of cytokine siganaling3) wasone regulatory factor of IFN signaling molecules, and it took part in the process of immuneresponse, then affected the Antiviral efficacy of IFN. Our studies were to investigate theexpressions and significances of SOCS3in cell models and difficult to treat chronichepatitis B patients’ PBMC.Methods: We selected two cell models, HepG2cells and HepG2.2.15cells, and both ofthem came from our laboratory. It should be pointed out that HepG2cells came frompeople’hematoma cell line, while HepG2.2.15cells were HepG2cells that had HBVreplication. We selected α-2a type IFN as Stimulating factor,and collected cells beforeusingn IFN and after6hour,12hour,24hour,48hour,72hour treatment of IFN. WB andReal-time PCR were used to detect the protein expression level and mRNA expression levelof SOCS3. Parallely, the IFN induced signaling pathway was also investigated in difficultto treat patients. These patients have experienced entecavir therapy for9to36month withthe achievement of HBV DNA negativity but with no HBeAg serum conversion. Fortypatients were randomized to group A and B with20in each group. Patients in group Areceived a two month of combination of entecavir plus Peg-IFN-alpha2a treatment followed by a total duration of48weeks Peg-IFN-alpha2a, while group B continuedentecavir treatment. PBMCs were isolated at baseline,4week,12week,24week posttreatment. The expression of SOCS3was detected both in protein expression level andmRNA expression level.Results: The results of WB and Real-time PCR showed that SCOS3could be detected inboth of cells before using IFN, and the expression in Hepg2.2.15cell was higher than inHepg2cell (p<0.05)；Compared with baseline, the expression of SOCS3in both HepG2cells and HepG2.2.15cells increased at6hour,12hour,24hour post IFN treatment andpeaked at6hour as measured by Real-time PCR（p<0.05）;compared with each other, theexpression of SOCS3in HepG2.2.15cells was higher than HepG2cells in each time,especially in6and12hour（p<0.05）. In difficult to treat chronic hepatitis B patients whoreceived IFN treatment, the expression of SOCS3significantly increased at both mRNAand protein levels. However, patients who did not receive IFN treatment, the expression ofSOCS3could not see any significant change.Conclusion: It was detected that the expression of SOCS3increased both in vivo and invitro studies, which pointed out that the HBV itself could irritate the expression of SOCS3.At the same time, the expression of SOCS3raised after using IFN, which pointed out thatIFN itself could d irritate the expression of SOCS3. In summary, the expression of SOCS3can be affected by HBV DNA and IFN, but the relationship between SOCS3and thetreatment effect of IFN need more studies.